BR112017024908A2 - usos terapêuticos da 4-cloroquinurenina - Google Patents

usos terapêuticos da 4-cloroquinurenina

Info

Publication number
BR112017024908A2
BR112017024908A2 BR112017024908A BR112017024908A BR112017024908A2 BR 112017024908 A2 BR112017024908 A2 BR 112017024908A2 BR 112017024908 A BR112017024908 A BR 112017024908A BR 112017024908 A BR112017024908 A BR 112017024908A BR 112017024908 A2 BR112017024908 A2 BR 112017024908A2
Authority
BR
Brazil
Prior art keywords
chloroquinurenine
therapeutic uses
conditions
treatment
pharmaceutical compositions
Prior art date
Application number
BR112017024908A
Other languages
English (en)
Inventor
Ralph Snodgrass H
Original Assignee
Vistagen Therapeutics Inc
Priority date (The priority date is an assumption and is not a legal conclusion. Google has not performed a legal analysis and makes no representation as to the accuracy of the date listed.)
Filing date
Publication date
Application filed by Vistagen Therapeutics Inc filed Critical Vistagen Therapeutics Inc
Publication of BR112017024908A2 publication Critical patent/BR112017024908A2/pt

Links

Classifications

    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K31/00—Medicinal preparations containing organic active ingredients
    • A61K31/185—Acids; Anhydrides, halides or salts thereof, e.g. sulfur acids, imidic, hydrazonic or hydroximic acids
    • A61K31/19—Carboxylic acids, e.g. valproic acid
    • A61K31/195—Carboxylic acids, e.g. valproic acid having an amino group
    • A61K31/197—Carboxylic acids, e.g. valproic acid having an amino group the amino and the carboxyl groups being attached to the same acyclic carbon chain, e.g. gamma-aminobutyric acid [GABA], beta-alanine, epsilon-aminocaproic acid, pantothenic acid
    • A61K31/198—Alpha-aminoacids, e.g. alanine, edetic acids [EDTA]
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K45/00—Medicinal preparations containing active ingredients not provided for in groups A61K31/00 - A61K41/00
    • A61K45/06—Mixtures of active ingredients without chemical characterisation, e.g. antiphlogistics and cardiaca
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P25/00—Drugs for disorders of the nervous system
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P25/00—Drugs for disorders of the nervous system
    • A61P25/02—Drugs for disorders of the nervous system for peripheral neuropathies
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P25/00—Drugs for disorders of the nervous system
    • A61P25/18—Antipsychotics, i.e. neuroleptics; Drugs for mania or schizophrenia
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P25/00—Drugs for disorders of the nervous system
    • A61P25/24—Antidepressants
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P27/00—Drugs for disorders of the senses
    • A61P27/16—Otologicals
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P3/00—Drugs for disorders of the metabolism
    • A61P3/08—Drugs for disorders of the metabolism for glucose homeostasis
    • A61P3/10—Drugs for disorders of the metabolism for glucose homeostasis for hyperglycaemia, e.g. antidiabetics

Abstract

composições farmacêuticas compreendendo l-4-cloroquinurenina e métodos terapêuticos associados são proporcionados para o tratamento de determinadas condições neurológicas e outras condições.
BR112017024908A 2015-05-22 2016-05-23 usos terapêuticos da 4-cloroquinurenina BR112017024908A2 (pt)

Applications Claiming Priority (2)

Application Number Priority Date Filing Date Title
US201562179924P 2015-05-22 2015-05-22
PCT/US2016/033733 WO2016191351A1 (en) 2015-05-22 2016-05-23 Therapeutic uses of l-4-chlorokynurenine

Publications (1)

Publication Number Publication Date
BR112017024908A2 true BR112017024908A2 (pt) 2018-07-31

Family

ID=57393671

Family Applications (1)

Application Number Title Priority Date Filing Date
BR112017024908A BR112017024908A2 (pt) 2015-05-22 2016-05-23 usos terapêuticos da 4-cloroquinurenina

Country Status (20)

Country Link
US (3) US20180140568A1 (pt)
EP (2) EP4108239A1 (pt)
JP (3) JP2018521007A (pt)
KR (1) KR20180015158A (pt)
CN (1) CN107949379A (pt)
AU (3) AU2016268153B2 (pt)
BR (1) BR112017024908A2 (pt)
CA (1) CA3024783A1 (pt)
DK (1) DK3297619T3 (pt)
EA (1) EA201792571A1 (pt)
ES (1) ES2925274T3 (pt)
HK (1) HK1257800A1 (pt)
IL (3) IL296380A (pt)
MX (1) MX2017014456A (pt)
PL (1) PL3297619T3 (pt)
PT (1) PT3297619T (pt)
SG (1) SG10202007661XA (pt)
SI (1) SI3297619T1 (pt)
WO (1) WO2016191351A1 (pt)
ZA (1) ZA201707874B (pt)

Families Citing this family (6)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
KR20210149905A (ko) 2013-01-22 2021-12-09 비스타젠 쎄라퓨틱스, 인크. L-4-클로로키뉴레닌의 투여형 및 치료적 용도
AU2020271853A1 (en) * 2019-04-09 2021-11-25 Vistagen Therapeutics, Inc. Genetic variants associated with response to treatment of neurological disorders
US20230181541A1 (en) * 2020-06-24 2023-06-15 Biohaven Therapeutics Ltd. Compositions and methods for treating obsessive-compulsive disorder
WO2022221423A1 (en) * 2021-04-13 2022-10-20 Vistagen Therapeutics, Inc. Treatment of autoimmune anti-nmda-receptor encephalitis
CN115677519A (zh) * 2021-07-22 2023-02-03 立科时代(武汉)生物科技有限公司 L-4-溴-犬尿氨酸及其在制备治疗抑郁症药物中的应用
WO2024011105A1 (en) * 2022-07-05 2024-01-11 Mahana Therapeutics, Inc. Methods and systems for treating tinnitus using digital therapeutics

Family Cites Families (13)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
US5484814A (en) 1991-02-28 1996-01-16 Merrell Dow Pharmaceuticals Inc. NMDA antagonists
AU2981099A (en) * 1998-03-09 1999-09-27 Trustees Of Tufts College Treatment of compulsive behaviours in man and animals
TW518218B (en) * 1999-05-27 2003-01-21 Merck Patent Gmbh Pharmaceutical compositions comprising 1-[4-(5-cyanoindol-3-yl)butyl]-4-(2-carbamoylbenzofuran-5-yl)piperazine or its physiologically acceptable salts for use in the treatment of sub-type anxiety disorders
AU2002229056A1 (en) * 2000-12-07 2002-06-18 Neuromolecular Inc. Methods for treating neuropsychiatric disorders with NMDA receptor antagonists
US20060063802A1 (en) * 2004-03-29 2006-03-23 Matthieu Guitton Methods for the treatment of tinnitus induced by cochlear excitotoxicity
MX2008013130A (es) * 2006-04-12 2008-11-19 Probiodrug Ag Inhibidores de enzima.
CA2606658A1 (en) * 2006-10-13 2008-04-13 Mike Tyers Compositions and methods for treating neurological disorders or damage
WO2009061935A2 (en) * 2007-11-06 2009-05-14 Emory University Methods of identifying safe nmda receptor antagonists
TW201026667A (en) * 2008-09-30 2010-07-16 Merz Pharma Gmbh & Co Kgaa Glycine b antagonists
CN104902883A (zh) * 2012-08-23 2015-09-09 斯图亚特·L·韦格 抗焦虑组合物、制剂及使用方法
KR20210149905A (ko) * 2013-01-22 2021-12-09 비스타젠 쎄라퓨틱스, 인크. L-4-클로로키뉴레닌의 투여형 및 치료적 용도
EP2970097B1 (en) 2013-03-14 2018-10-31 Vistagen Therapeutics, Inc. Methods for the synthesis of chiral kynurenine compounds
EP2970080A4 (en) 2013-03-14 2017-01-18 Vistagen Therapeutics, Inc. Synthesis of chiral kynurenine compounds and intermediates

Also Published As

Publication number Publication date
US20190321317A1 (en) 2019-10-24
AU2016268153A1 (en) 2017-12-14
IL296380A (en) 2022-11-01
WO2016191351A1 (en) 2016-12-01
HK1257800A1 (zh) 2019-11-01
ZA201707874B (en) 2020-01-29
SI3297619T1 (sl) 2023-02-28
JP2018521007A (ja) 2018-08-02
CN107949379A (zh) 2018-04-20
US20240122887A1 (en) 2024-04-18
IL255770A (en) 2018-01-31
PT3297619T (pt) 2022-08-05
PL3297619T3 (pl) 2023-02-13
CA3024783A1 (en) 2016-12-01
EA201792571A1 (ru) 2018-06-29
EP3297619A4 (en) 2019-01-02
AU2023282234A1 (en) 2024-01-18
IL255770B (en) 2021-09-30
KR20180015158A (ko) 2018-02-12
JP2022064908A (ja) 2022-04-26
SG10202007661XA (en) 2020-09-29
DK3297619T3 (da) 2022-08-15
ES2925274T3 (es) 2022-10-14
AU2021209279A1 (en) 2021-08-19
EP3297619B1 (en) 2022-07-06
IL285882A (en) 2021-09-30
EP4108239A1 (en) 2022-12-28
AU2016268153B2 (en) 2021-08-12
AU2021209279B2 (en) 2023-09-14
MX2017014456A (es) 2018-03-16
JP2024050575A (ja) 2024-04-10
US20180140568A1 (en) 2018-05-24
EP3297619A1 (en) 2018-03-28

Similar Documents

Publication Publication Date Title
BR112017024384A2 (pt) bactérias modificadas para reduzir hiperfenilalaninemia
PH12018500586A1 (en) Farnesoid x receptor agonists and uses thereof
AU2024202345A1 (en) Nucleic acid carriers and therapeutic methods of use
DK3616720T3 (da) Farmaceutisk sammensætning til cancerbehandling
DK3889145T3 (da) 8-cyano-5-piperidino-quinoliner som TLR7/8-antagonister og anvendelser deraf til behandling af immunsygdomme
IL255509B (en) Compounds as modulators of ccr2, pharmaceutical preparations containing them and their use in the treatment of diseases
BR112017012342A2 (pt) compostos inibitórios de bcl-xl e conjugados de anticorpo-fármaco incluindo os mesmos
BR112017011923A2 (pt) bactéria modificada para tratar doenças associadas com hiperamonemia
MX2020009780A (es) Compuestos de inhibidor de autotaxina.
TW201613901A (en) New compounds
MY187540A (en) Compounds active towards bromodomains
EA201791874A1 (ru) Фторированные ингибиторы лизилоксидазоподобного фермента-2 и их применение
MX2017011997A (es) Carbamatos de piperacina y metodos de preparacion y uso.
GB2541571A (en) Pharmaceutical compositions
BR112017024908A2 (pt) usos terapêuticos da 4-cloroquinurenina
CL2018000565A1 (es) Compuestos derivados de piridinona dicarboxamida, inhibidores de bromodominio; composicion farmaceutica; combinacion farmaceutica; utiles en el tratamiento de enfermedades autoinmunitarias, inflamatorias, virales y cancer, entre otras.
IL258854A (en) Preparations containing cannabidiol and secondary medicinal agents for cancer treatment
TR201901077T4 (tr) Kanser Veya Enfeksiyon Tedavisine Yönelik Birleşik Preparasyonlar
BR112016018062A2 (pt) compostos terapêuticos, composição farmacêutica e usos
CO2017010399A2 (es) Imidazopirazinonas como inhibidores de pde1
EA201692313A1 (ru) Производные индолизина в качестве ингибиторов фосфоинозитид-3-киназ
NI201600070A (es) Inhibidores tetracíclicos de autotaxina
BR112018070497A2 (pt) métodos e formulações farmacêuticas para tratamento de condições oculares
BR112018012304A2 (pt) composições e métodos para diminuir expressão de tau
ZA201703467B (en) Methods of treating ocular conditions

Legal Events

Date Code Title Description
B07D Technical examination (opinion) related to article 229 of industrial property law [chapter 7.4 patent gazette]

Free format text: DE ACORDO COM O ARTIGO 229-C DA LEI NO 10196/2001, QUE MODIFICOU A LEI NO 9279/96, A CONCESSAO DA PATENTE ESTA CONDICIONADA A ANUENCIA PREVIA DA ANVISA. CONSIDERANDO A APROVACAO DOS TERMOS DO PARECER NO 337/PGF/EA/2010, BEM COMO A PORTARIA INTERMINISTERIAL NO 1065 DE 24/05/2012, ENCAMINHA-SE O PRESENTE PEDIDO PARA AS PROVIDENCIAS CABIVEIS.

B07E Notification of approval relating to section 229 industrial property law [chapter 7.5 patent gazette]
B06U Preliminary requirement: requests with searches performed by other patent offices: procedure suspended [chapter 6.21 patent gazette]
B07A Application suspended after technical examination (opinion) [chapter 7.1 patent gazette]
B154 Notification of filing of divisional application [chapter 15.50 patent gazette]

Free format text: O PEDIDO FOI DIVIDIDO NO BR122023018047-0 PROTOCOLO 870230078956 EM 05/09/2023 16:50.

B09B Patent application refused [chapter 9.2 patent gazette]
B12B Appeal against refusal [chapter 12.2 patent gazette]